IL257282B - Compounds 2-(4-aminocyclohexylamino)-4-(pyrazol-4-yl)pyrimidine - Google Patents
Compounds 2-(4-aminocyclohexylamino)-4-(pyrazol-4-yl)pyrimidineInfo
- Publication number
- IL257282B IL257282B IL257282A IL25728218A IL257282B IL 257282 B IL257282 B IL 257282B IL 257282 A IL257282 A IL 257282A IL 25728218 A IL25728218 A IL 25728218A IL 257282 B IL257282 B IL 257282B
- Authority
- IL
- Israel
- Prior art keywords
- aminocyclohexylamino
- pyrazol
- pyrimidine compounds
- pyrimidine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200846P | 2015-08-04 | 2015-08-04 | |
| US201562268750P | 2015-12-17 | 2015-12-17 | |
| PCT/IL2016/050852 WO2017021969A1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL257282A IL257282A (en) | 2018-03-29 |
| IL257282B true IL257282B (en) | 2021-06-30 |
Family
ID=56738143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257282A IL257282B (en) | 2015-08-04 | 2018-01-31 | Compounds 2-(4-aminocyclohexylamino)-4-(pyrazol-4-yl)pyrimidine |
Country Status (23)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3331877B1 (en) * | 2015-08-04 | 2021-09-22 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Pyrazole pyrimidine derivative and uses thereof |
| ES2902885T3 (es) | 2017-02-01 | 2022-03-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| AU2019219678A1 (en) | 2018-02-08 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CN114423752B (zh) * | 2019-06-03 | 2025-06-24 | 耶路撒冷希伯来大学伊萨姆研究发展公司 | 吡唑化合物的非吸湿性结晶盐和其药物组合物与用途 |
| WO2021000957A1 (zh) * | 2019-07-04 | 2021-01-07 | 北京国鸿生物医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| PH12022550361A1 (en) | 2019-08-14 | 2023-02-27 | Incyte Corp | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
| TW202140460A (zh) * | 2020-01-13 | 2021-11-01 | 美商拜歐斯瑞克斯公司 | 吡唑基嘧啶及其用途 |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| CA3177058A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aryl piperidines as monoacylglycerol lipase modulators |
| WO2022204220A1 (en) * | 2021-03-24 | 2022-09-29 | Biotheryx, Inc. | Pyrazolylpyrimidines for treating malignant solid tumor |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11752151B2 (en) | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2025199440A1 (en) * | 2024-03-21 | 2025-09-25 | Edgewood Oncology | Methods of treating liposarcoma using a pyrazole compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002046184A1 (en) * | 2000-12-05 | 2002-06-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US6884804B2 (en) | 2001-05-16 | 2005-04-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and other protein kinases |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| ZA200607639B (en) | 2004-03-30 | 2008-05-28 | Taisho Pharmaceutical Co Ltd | Pyrimidine derivatives and methods of treatment related to the use thereof |
| JP2007145819A (ja) * | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| JP2009538352A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ アクチボラグ | 細胞増殖を阻害するための薬剤としての２−カルボシクロアミノ−４−イミダゾリルピリミジン類 |
| CA2707989A1 (en) * | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| BR112014010563B1 (pt) * | 2011-11-04 | 2021-01-12 | Jasco Pharmaceuticals, LLC | compostos inibidores da aminopirimidina quinase |
| EP3049086A4 (en) * | 2013-09-27 | 2017-02-22 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US10047070B2 (en) * | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| EP3331877B1 (en) | 2015-08-04 | 2021-09-22 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Pyrazole pyrimidine derivative and uses thereof |
| ES2902885T3 (es) * | 2017-02-01 | 2022-03-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer |
| AU2019219678A1 (en) | 2018-02-08 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
-
2016
- 2016-08-04 EP EP16753709.1A patent/EP3331877B1/en active Active
- 2016-08-04 WO PCT/IL2016/050852 patent/WO2017021969A1/en not_active Ceased
- 2016-08-04 AU AU2016304464A patent/AU2016304464B2/en active Active
- 2016-08-04 SI SI201631426T patent/SI3331877T1/sl unknown
- 2016-08-04 MX MX2018001395A patent/MX384172B/es unknown
- 2016-08-04 DK DK16753709.1T patent/DK3331877T3/da active
- 2016-08-04 PL PL16753709T patent/PL3331877T3/pl unknown
- 2016-08-04 KR KR1020187006128A patent/KR102698366B1/ko active Active
- 2016-08-04 RS RS20211558A patent/RS62728B1/sr unknown
- 2016-08-04 PT PT167537091T patent/PT3331877T/pt unknown
- 2016-08-04 US US15/748,536 patent/US10376511B2/en active Active
- 2016-08-04 RU RU2018107668A patent/RU2735522C2/ru active
- 2016-08-04 CN CN201680059148.XA patent/CN108137562B/zh active Active
- 2016-08-04 SM SM20210720T patent/SMT202100720T1/it unknown
- 2016-08-04 CA CA2994644A patent/CA2994644A1/en active Pending
- 2016-08-04 ES ES16753709T patent/ES2901349T3/es active Active
- 2016-08-04 HU HUE16753709A patent/HUE057607T2/hu unknown
- 2016-08-04 HR HRP20211949TT patent/HRP20211949T1/hr unknown
- 2016-08-04 JP JP2018525826A patent/JP7083309B2/ja active Active
- 2016-08-04 LT LTEPPCT/IL2016/050852T patent/LT3331877T/lt unknown
-
2018
- 2018-01-31 IL IL257282A patent/IL257282B/en active IP Right Grant
- 2018-01-31 ZA ZA2018/00671A patent/ZA201800671B/en unknown
-
2019
- 2019-08-12 US US16/538,550 patent/US10960003B2/en active Active
-
2021
- 2021-02-10 AU AU2021200839A patent/AU2021200839A1/en not_active Abandoned
- 2021-03-29 US US17/215,959 patent/US11925641B2/en active Active
- 2021-12-21 CY CY20211101124T patent/CY1124898T1/el unknown
-
2024
- 2024-02-05 US US18/432,931 patent/US20250049793A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257282B (en) | Compounds 2-(4-aminocyclohexylamino)-4-(pyrazol-4-yl)pyrimidine | |
| SG11201802832UA (en) | Pyrimidine compound | |
| IL255668A (en) | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as jak inhibitors | |
| GB201510019D0 (en) | Compounds | |
| IL250022A0 (en) | New converted pyrimidine compounds | |
| GB201508747D0 (en) | Compounds | |
| GB201514754D0 (en) | Compounds | |
| GB201514751D0 (en) | Compounds | |
| GB201518365D0 (en) | Compounds | |
| GB201520500D0 (en) | Compounds | |
| SG10201913525QA (en) | Pyrimidine derivative | |
| GB201520499D0 (en) | Compounds | |
| GB201520419D0 (en) | Compounds | |
| GB201508864D0 (en) | Compounds | |
| GB201510493D0 (en) | Compounds | |
| GB201500702D0 (en) | Alignment aid | |
| GB201503926D0 (en) | Compounds | |
| GB201501115D0 (en) | Compounds | |
| IL253147A0 (en) | Pyrazole compounds | |
| GB201508857D0 (en) | Compounds | |
| ZA201704292B (en) | Pyrazole compounds | |
| AU2016165V (en) | ZMM-018 Zoysia macrantha | |
| AU2016166V (en) | ZMW-019 Zoysia macrantha | |
| AU2015311V (en) | LSA01 Zoysia macrantha | |
| GB201521440D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |